{"id":416042,"title":"Guidance Policy - Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research Policy (POL-0053) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-26","captureTimestamp":"2026-01-26T16:12:52.598000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/guidance-policy-use-positron-emitting-radiopharmaceuticals-basic-research-0053.html","snippet":"Guidance Policy - Use of Positron Emitting Radiopharmaceuticals (PERs) in Basic Research Policy (POL-0053) (February 24, 2006) Contact Name: Drug GMP Inspection Unit Tel: 613-952-9319 Fax: 613-957-6709 E-Mail: GMP_Questions_BPF@hc-sc.gc.ca (PDF Version - 112 K) Health Products…","rawSnapshotUrl":"/api/snapshots/raw/416042","browseUrl":"https://replay.healtharchive.ca/job-6/20260126161252/https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/information-health-product/drugs/guidance-policy-use-positron-emitting-radiopharmaceuticals-basic-research-0053.html#ha_snapshot=416042","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}